Abstract: The disclosure relates to a composition of nanoparticles as carrier for HPV-derived immunogenic fragments and the use of the composition for medical purposes, in particular for immunoprophylaxis or immunotherapy. The invention also relates to a vaccine containing the composition and/or nanoparticles.

Abstract: The disclosure relates to a composition of nanoparticles as carrier for pharmaceutically acceptable compounds, a method for the preparation of the composition and the use of the composition for medical purposes, in particular for immunoprophylaxis or immunotherapy. The invention also relates to a vaccine containing the composition.

Abstract: The invention relates to a method for detecting epileptic or psychogenic seizures, comprising the steps of: a. recording a large number of temporally sequential parameter values for a parameter type, wherein a parameter value is determined on the basis of a series of temporally sequential RR intervals, the series of temporally sequential parameter values preferably differing in that the series that served as the basis for determining the following parameter value includes, in place of the oldest RR interval of the series that served as the basis for determining the preceding parameter value (preceding series), the RR interval temporally subsequent to the most recent RR interval of the preceding series, b. comparing the time course of the parameter values with the time course of parameter values for the same parameter type that had been determined according to method step a, and the determination thereof is based on RR intervals that indicate a seizure (parameter reference values), c.

Abstract: The invention relates to a passive transponder having at least one coil, the transponder having an electrically conductive shield which covers the windings of the coil from both sides. A central region of the coil around which the windings are wound is not covered by the shield. In the surfaces, in which the shield covers the windings, the shield has at least one discontinuity by which a current flow in the shield can be prevented.

Abstract: The invention relates to VLP derived from human polyoma virus loaded with a drug (cargo) as a drug delivery system for transporting said drug into the CNS, in particular of living humans.

Abstract: The invention relates to an implantation device for implanting a vascular implant, which enables a vascular implant to be easily positioned and to be discharged in a slip-free manner.

Abstract: The invention relates to a passive transponder system comprising a first or second conductor loop structure and a first and a second capacitive pressure sensor, wherein each conductor loop structure is coupled to one of said capacitive pressure sensors to form a resonant circuit, and the first conductor loop structure is positioned at a non-vanishing angle in relation to the second conductor loop structure. The resonant frequencies of the resonant circuits are selected such that they do not overlap to result in beating. The invention also relates to a pressure wave measuring device comprising such a passive transponder system, and a readout unit.

Abstract: The invention relates to a passive transponder having at least one coil, the transponder having an electrically conductive shield which covers the windings of the coil from both sides. A central region of the coil around which the windings are wound is not covered by the shield. In the surfaces, in which the shield covers the windings, the shield has at least one discontinuity by which a current flow in the shield can be prevented.

Abstract: The invention relates to a transponder system having at least one passive transponder, which has a resonant circuit having a variable resonant frequency, and having a readout device, wherein the readout device is designed to modify a frequency of the readout signal to the variable resonant frequency of the resonant circuit. The invention additionally relates to a method for readout of a passive transponder, which has a resonant circuit having a variable resonant frequency.

Abstract: The invention relates to VLP derived from human polyoma virus loaded with a drug (cargo) as a drug delivery system for transporting said drug into the CNS, in particular of living humans.

Abstract: The invention relates to VLP derived from human polyoma virus loaded with a drug (cargo) as a drug delivery system for transporting said drug into the CNS, in particular of living humans.

Abstract: The invention relates to a method for purifying compositions containing virus-like particles (VLP), wherein a VLP-containing composition is filtered through a filter medium, in particular through a membrane, having a molecular weight cut off (MWCO) of more than 30 kDa, and the cell culture supernatant of VLP-expressing cells is used as a VLP-containing composition. The invention further relates to a VLP-containing composition which can be produced by this method.

Abstract: The disclosure relates to a fusion protein comprising a VP1 binding protein and an exogenous peptide, wherein the exogenous peptide comprises a cargo-securing peptide (CSP) and/or an endosome translocating peptide (ETP) and to virus like particles (VLP) comprising the fusion protein for use as drug delivery system. Also provided are polynucleotides encoding the fusion protein, suitable expression vectors, host cells, production methods for the fusion protein and the VLP comprising the fusion protein.

Abstract: The invention relates to a method for purifying compositions containing virus-like particles (VLP), wherein a VLP-containing composition is filtered through a filter medium, in particular through a membrane, having a molecular weight cut off (MWCO) of more than 30 kDa, and the cell culture supernatant of VLP-expressing cells is used as a VLP-containing composition. The invention further relates to a VLP-containing composition which can be produced by this method.